Novo Nordisk's next-gen obesity drug CagriSema had investors excited. Now they're not so sure
Novo Nordisk's hopes of heralding a new era of obesity treatment with its next-generation CagriSema drug may be in doubt ...
Zacks Investment Research on MSN14h
VKTX Finishes Enrolment in Mid-Stage Study on Oral Weight-Loss Drug
Viking Therapeutics VKTX announced that it has completed enrolling study participants in the phase II VENTURE-Oral Dosing ...
Metsera Reports Fourth Quarter and Full Year 2024 Financial Results and Continued Portfolio Progress
MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, is being studied in multiple Phase 2b clinical trials with read-outs ...
Metsera reports Q4 EPS ($3.52) vs. (94c) last year
Metsera ,” said Whit Bernard, CEO. “We advanced MET-097i, our monthly, fully-biased GLP-1 RA injectable, from f ...
NBC 10 Philadelphia3d
Novo Nordisk's next-gen obesity drug CagriSema had investors excited. Now they're not so sure
CagriSema is a combination of cagrilintide — a nascent form of weight loss treatment known as an amylin analog — and semaglutide, the active ingredient in Wegovy. It was hoped that the drug ...